Skye Bioscience Inc (SKYE)

Currency in USD
3.8800
0.0000(0.00%)
Real-time Data·

SKYE Earnings

Latest Release
May 08, 2025
EPS / Forecast
-0.28 / -0.21
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
03/2025-0.28/-0.21--/---33.33%--Free Sign Up
12/2024-0.24/-0.19--/---26.32%--Free Sign Up
09/2023--/----/------Free Sign Up
06/2023--/----/------Free Sign Up
03/2023--/----/------Free Sign Up
12/2022-0.01/----/------Free Sign Up
09/2022-0.01/----/------Free Sign Up
06/2022-0.01/----/------Free Sign Up
03/2022-0.01/----/------Free Sign Up
12/2021-0.01/----/------Free Sign Up

All numbers in

Skye Bioscience Inc Earnings Call Summary for Q1/2025

  • R&D expenses rose to $7.2M in Q1 2025, up from $1.9M in Q1 2024; cash reserves at $59.2M, funding operations through Q1 2027
  • Completed enrollment in Phase IIa CBEYOND trial; targeting obesity treatment market with Nimazumab therapy
  • Net loss of $11.1M for Q1 2025; stock unchanged at $2.55, reflecting stable investor sentiment
  • Expects top-line weight loss data in late Q3/early Q4; plans to initiate Phase 2b monotherapy dose-ranging study
  • CEO highlights robust CB1 inhibition; CSO expresses confidence in drug's clinical potential
Last Updated: 08/05/2025, 22:40
Read Full Transcript

FAQ

What Is Skye Bioscience's Earnings Per Share (TTM)?

The Skye Bioscience EPS (TTM) is -0.83.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.